Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 3/20 | 0.61 |
| ▸ | GPR132 | Q9UNW8 | 3/20 | 0.60 |
| ▸ | GPR34 | Q9UPC5 | 8/20 | 0.60 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.59 |
| ▸ | MME | P08473 | 1/20 | 0.58 |
| ▸ | ACE | P12821 | 1/20 | 0.58 |
| ▸ | CPA1 | P15085 | 1/20 | 0.58 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6662616 | 0.92 | PPARG (0.60) | PPARGGPR132GPR34ALDH1A1GAA | |
| SCHEMBL1123227 | 0.85 | PTPN1 (0.63) | PPARGGPR132GPR34PTPN1MME | |
| SCHEMBL1122641 | 0.84 | PTPN1 (0.77) | PPARGGPR132GPR34PTPN1MME | |
| SCHEMBL6516719 | 0.84 | ITGB1 (0.59) | — | |
| SCHEMBL18114395 | 0.83 | GPR132 (0.81) | PPARGGPR132GPR34PTPN1 | |
| SCHEMBL1123299 | 0.82 | GPR132 (0.77) | PPARGGPR132GPR34PTPN1MME | |
| SCHEMBL16541078 | 0.82 | PPARG (0.70) | PPARGGPR132GPR34MMEACE | |
| SCHEMBL1123033 | 0.82 | GPR132 (0.77) | PPARGGPR132GPR34PTPN1MME | |
| SCHEMBL6182299 | 0.82 | GPR132 (0.77) | PPARGGPR132GPR34PTPN1MME | |
| SCHEMBL753187 | 0.82 | PPARG (0.70) | PPARGGPR132GPR34MMEACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050215598-A1 | Phenylalanine derivatives | CELLTECH R&D LTD. (GB) | 2005-09-29 | — | — | US | disclosed |
| EP-1056714-B1 | PHENYLALANINE DERIVATIVES AS INHIBITORS OF ALPHA4 INTEGRINS | CELLTECH THERAPEUTICS LTD (GB) | 2004-08-11 | — | — | EP | disclosed |
| US-20030166691-A1 | Phenylalanine derivatives | ARCHIBALD SARAH CATHERINE (GB) | 2003-09-04 | — | — | US | disclosed |
| US-6555562-B1 | 2-Carboxybenzoyl-(N'-3,5-dichloroisonicotinoyl)-L-4aminophenyl alanine, for example; inhibit the binding of alpha-4 integrins to their ligands, use to treat immune or inflammatory disorders | CELLTECH R&D LIMITED (GB) | 2003-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166691-A1 | Phenylalanine derivatives | VCAM1, PAH, ITGB4 | PPARG 734/4885GPR132 875/4885GPR34 148/4885 |
| US-20050215598-A1 | Phenylalanine derivatives | PAH, ITGB4, VCAM1 | PPARG 508/4885GPR132 732/4885GPR34 194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.